Rock Creek Pharmaceuticals, a Sarasota-based drug development company focused on chronic inflammatory disease and neurologic disorders, announced it filed a second quarter report with the Securities Exchange Commission. For the three months that ended June 30, the company reported net sales of $0.7 million compared to $2.5 million for the same period in 2013. The decrease of 71 percent was attributable exclusively to decreased Anatabloc sales volume driven by significantly reduced promotion and marketing expenditures associated with the administrative status of Anatabloc during the period, company officials said. The company also reported positive gross profits of $0.4 million compared to a gross profit of $1 million for the same period in 2013. The company had a net loss of approximately $12.7 million for the three months ended June 30 compared to a net loss of approximately $8.7 million for the same period in 2013. The increase in net loss was primarily due to increases in stock-based compensation and severance costs, offset by lower sales and marketing expenses and legal expenditures, officials said.

Rock Creek Pharmaceuticals